Gilead Sciences | GILD - Operating Profit


Gilead Sciences reported $3.85B in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Glaxosmithkline GBP 2.29B 3.08M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
J&J USD 7.48B 860M Jun/2026
Merck USD 840M 2.72B Jun/2026
Moderna USD -815M 573M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 2.38B 449M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
United Therapeutics USD 330.8M 5M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026